Full Press Release Details
Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application.
BIIB
Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
Key Takeaway: Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
Price reaction · baseline $220.75 (2024-03-21 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis